contact

Dr. Felicitas Hitz

titel Dr.med.

first name Felicitas

last name Hitz

country Switzerland

phone number 071 494 10 66

e-mail felicitas.hitz@kssg.ch

2

publications

title

journalpaper/review

Hitz F, Zucca E, Pabst T, Fischer N, Cairoli A, Samaras P, Caspar C B,Mach N, Krasniqi F, Schmidt A, Rothermundt C, Enoiu M, Eckhardt K,Berardi Vilei S, Rondeau S, Mey U. Rituximab, bendamustine andlenalidomide in patients with aggressive B-cell lymphoma not eligible foranthracycline-based therapy or intensive salvage chemotherapy - SAKK38/08. Br J Haematol 2016;.

Hundsberger T, Brügge D, Hitz F. Leptomeningeal lymphomatosis fromlarge granular lymphocyte leukaemia. J Neurol 2014; 261:1221-1222.

Diem S, Ess S, Cerny T, Früh M, Hitz F. Diffuse large B-cell lymphoma inelderly patients: a retrospective analysis. Eur J Intern Med 2014;25:577-82.

Weisshaupt C, Hitz F, Albrich W C, Omlin A. Pulmonary actinomycosis andHodgkin's disease: when FDG-PET may be misleading. BMJ Case Rep2014; 2014:.

Silzle T, Hitz F. A hairy issue. Blood 2014; 123:958.

Clough-Gorr K M, Noti L, Brauchli P, Cathomas R, Fried M R, Roberts G,Stuck A E, Hitz F, Mey U. The SAKK cancer-specific geriatric assessment(C-SGA): a pilot study of a brief tool for clinical decision-making in oldercancer patients. BMC Med Inform Decis Mak 2013; 13:93.

Früh M, Besrour H, Gillessen Sommer S, Joerger M, Hitz F, Savidan A,Cerny T, Ess S. Management of elderly patients with advanced non-smallcell lung cancer: a single-center experience. Chemotherapy 2013;59:42-50.

Silzle T, Glaser-Gallion N, Hitz F. Posterior reversible encephalopathysyndrome during induction chemotherapy for acute myeloid leukaemia.Eur J Haematol 2013; 92:90.

3

publications

title

journalpaper/review

Hitz F, Diem S, Haile S, Ess S, Cerny T, Mey U. Outcome of mantle celllymphoma patients treated at a single institution over the past decade.Hematol Oncol 2013;.

Joerger M, Huitema A D R, Koeberle D, Rosing H, Beijnen J H, Hitz F,Cerny T, Schellens J H M, Gillessen Sommer S. Safety and pharmacologyof gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction. Cancer Chemother Pharmacol2013; 73:113-24.

Hitz F, Ribi K, Li Q, Klingbiel D, Cerny T, Koeberle D. Predictors ofsatisfaction with treatment decision, decision-making preferences, andmain treatment goals in patients with advanced cancer. Support CareCancer 2013; 21:3085-93.

Hitz F, Klingbiel D, Omlin A, Riniker S, Zerz A, Cerny T. Athrombogeniccoating of long-term venous catheter for cancer patients: a prospective,randomised, double-blind trial. Ann Hematol 2011; 91:613-20.

Hinder R, Hitz F, Brugnolaro-Friedrich C, Stöckli S. [A Rare Cause of aCervical Lymphadenopathy.]. Praxis (Bern 1994) 2011; 100:105-108.

Hitz F, Martinelli G, Zucca E, von Moos R, Mingrone W, Simcock M,Peterson J, Cogliatti S B, Bertoni F, Zimmermann D R, Ghielmini M, SwissGroup for Clinical Cancer Research (SAKK), Bern, Switzerland . Amulticentre phase II trial of gemcitabine for the treatment of patientswith newly diagnosed, relapsed or chemotherapy resistant mantle celllymphoma: SAKK 36/03. Hematological oncology 2009; 27:154-9.

4

publications

title

journalpaper/review

Beyer V, Mühlematter D, Parlier V, Cabrol C, Bougeon-Mamin S,Solenthaler M, Tobler A, Pugin P, Gregor M, Hitz F, Hess U, Chapuis B,Laurencet F, Schanz U, Schmidt P M, van Melle G, Jotterand M. Polysomy8 defines a clinico-cytogenetic entity representing a subset of myeloidhematologic malignancies associated with a poor prognosis: report on acohort of 12 patients and review of 105 published cases. Cancer geneticsand cytogenetics 2005; 160:97-119.

Cerny T, Hitz F, Gillessen Sommer S. [Mabthera for treatment ofmalignant lymphoma]. Therapeutische Umschau. Revue thérapeutique2004; 61:379-83.

conferencepaper/poster

Neumair P, Joos L, Warschkow R, Ess S, Hitz F, Früh M, Brutsche M, BatyF, Krähenbühl S, & Joerger M (2016). Chemotherapy is not superior toerlotinib in pretreated patients with advanced non-small cell lung cancer(NSCLC): A retrospective study: Abstrakt 169P. In J Thorac Oncol. 11(4Suppl) (pp. 131): Elsevier.

Schallegger K, Brügge D, Hitz F, Hundsberger T, Cathomas R, & PlasswilmL (2012). Case Report of a patient with LGL-Leukemia who Developed aLeptomeningeal Lymphomatosis. In (pp. 128): SASRO.

5

projects

title status

Rituximab with or without Ibrutinib for untreated patients withadvanced follicular lymphoma in need of therapy. Arandomized, double-blinded, SAKK and NLG collaborative PhaseII trial

ongoing- followup

Combination of ibrutinib and bortezomib followed by ibrutinibmaintenance to treat patients with relapsed and refractorymantle cell lymphoma; a multicenter Phase I/II trial

ongoing- followup

HOVON 103 / SAKK 30/10 protocol Tosedostat scheduled

Disease-specific profiles of decision-making processes atmultidisciplinary team conferences

ongoing- followup

6

projects

title status

A randomized, open-label, multicentre, two-arm phase IIIcomparative study assessing the role of mediastinal radio-therapy after Rituximab containing chemotherapy regimens topatients with newly diagnosed Primary Mediastinal Large B-CellLymphoma (PMLBCL

ongoing- followup

7

projects

title status

A phase I study of Inotuzumab Ozogamicin (CMC-544) incombination with Temsirolimus (CCI-779) in patients withrelapsed or refractory CD22-positive B-cell Non Hodgkin’sLymphomas

ongoing- followup

8

projects

title status

Master Protokoll: A Program of randomized phase IImulticenter sudies to assess the tolerability and efficacy of theaddition of new drugs to standard induction chemotherapy inAML and RAEB ≥ 66 years and cery poor risk AML ≥ years

ongoing- followup

SAKK 39/10 automat-icallyclosed

Therapieoptimierungsstudie in der Primärtherapie des frühenHodgkin Lymphoms: Therapiestratifizierung mittels FDG-PET

ongoing- followup

Randomized study with a run-in feasibility phase to assess theadded value of Clofarabine in combination with standardremission-induction chemotherapy in patients aged 18-65 yearswith previously untreated acute myeloid leukemia (AML) ormyelodysplasia (MDS) RAEB with IPSS (grösser gleich 1.5) Amulticenter phase III trial

ongoing- followup

Phase I trial of nelfinavir and bortezomib in advancedhematologic malignancies

automat-icallyclosed

9

projects

title status

Phase III trial of combined immunochemotherapy withFludarabine, Cyclophosphamide and Rituximab (FCR) versusBendamustine and Rituximab (BR) in patients with previouslyuntreated chronic lymphocytic leukaemia

automat-icallyclosed

Retrospektiver Untersuch von Patienten mit HodgkinLymphomen des Krebsregister St. Gallen/Appenzell undGraubünden/Glarus, die innerhalb oder ausserhalb einesStudienprotokolls behandelt werden

ongoing- followup

10

projects

title status

Krankheitsverlauf von Hodgkin Patienten, welche innerhalbrespektive ausserhalb eines Studienprotokolls in den KantonenSt.Gallen / Appenzell respektive Graubünden / Glarusbehandelt wurden

ongoing- followup

Smiley-Projekt: Prädiktive Faktoren einer gutenEntscheidungsfindung für eine Palliativtherapie bei Patienten imOnkologie-Netzwerk KSSG

automat-icallyclosed

Radioimmunotherapy Registry Switzerland automat-icallyclosed

Rituximab, bendamustine and lenalidomide in patients withrelapsed or refractory aggressive B-cell lymphoma not eligiblefor high dose chemotherapy. A phase I/II trial

automat-icallyclosed

11

projects

title status

Therapieoptimierungsstudie in der Primärtherapie desfortgeschrittenen Hodgkin Lymphoms: Therapiestratifizierungmittels FDG-PET

ongoing- followup

Phase IB (or II) Trial of Nelfinavir + Lenalidomide in Patientswith Multiple Myeloma that have replapsed duringLenalidomide-containing therapy

scheduled

12

projects

title status

An open-label, multi-centre, dose escalating, phase I/II studyto investigate the safety and tolerability of RO5072759 given asmonotherapy in patients with CD 20+ malignant disease

automat-icallyclosed

A randomized trial assessing the role of arsenic automat-icallyclosed

13

projects

title status

Master protocol for mantle cell lymphoma A multicenterstratified phase II trial testing Everolimus (RAD001) for thetreatment of patientswith newly diagnosed and relapsed ortherapy resistant mantle cell lymphoma

ongoing- followup

14

projects

title status

Ibritumomab tiuxetan and high-dose melphalan as conditioningregimen before autologous stem cell transplantation for elderlypatients with lymphoma in relapse or resistant tochemotherapy. A multicenter phase I trial

completed

Qualitätssicherungsprotokoll zur Effektivitätssteigerung in derPrimärtherapie des intermediären Morbus Hodgkin (4 x ABVD +IF vs. 2 x BEACOPP eskaliert + 2 x ABVD + IF)

ongoing- followup